Category Archives: Biotechnology

This is a whole new era where were moving beyond little edits on single genes to being able to write whatever we want throughout the genome.

-George Church, Professor of Genetics at Harvard Medical School

Click here to see this page in other languages:JapaneseRussian

How are scientists putting natures machinery to use for the good of humanity, and how could things go wrong?

Biotechnology is nearly as old as humanity itself. The food you eat and the pets you love? You can thank our distant ancestors for kickstarting the agricultural revolution, using artificial selection for crops, livestock, and other domesticated animals. When Edward Jenner invented vaccines and when Alexander Fleming discovered antibiotics, they were harnessing the power of biotechnology. And, of course, modern civilization would hardly be imaginable without the fermentation processes that gave us beer, wine, and cheese!

When he coined the term in 1919, the agriculturalist Karl Ereky described biotechnology as all lines of work by which products are produced from raw materials with the aid of living things. In modern biotechnology, researchers modify DNA and proteins to shape the capabilities of living cells, plants, and animals into something useful for humans. Biotechnologists do this by sequencing, or reading, the DNA found in nature, and then manipulating it in a test tube or, more recently, inside of living cells.

In fact, the most exciting biotechnology advances of recent times are occurring at the microscopic level (and smaller!) within the membranes of cells. After decades of basic research into decoding the chemical and genetic makeup of cells, biologists in the mid-20th century launched what would become a multi-decade flurry of research and breakthroughs. Their work has brought us the powerful cellular tools at biotechnologists disposal today. In the coming decades, scientists will use the tools of biotechnology to manipulate cells with increasing control, from precision editing of DNA to synthesizing entire genomes from their basic chemical building blocks. These cells could go on to become bomb-sniffing plants, miracle cancer drugs, or de-extincted wooly mammoths. And biotechnology may be a crucial ally in the fight against climate change.

But rewriting the blueprints of life carries an enormous risk. To begin with, the same technology being used to extend our lives could instead be used to end them. While researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious: the virus could escape, or someone could weaponize the research. And the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. The most sophisticated biotechnology may be no match for Murphys Law.

While the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial applications and more worrisome risks. Adding to concerns, DIY scientists are increasingly taking biotech tools outside of the lab. For now, many of the benefits of biotechnology are concrete while many of the risks remain hypotheticals, but it is better to be proactive and cognizant of the risks than to wait for something to go wrong first and then attempt to address the damage.

Satellite images make clear the massive changes that mankind has made to the surface of the Earth: cleared forests, massive dams and reservoirs, millions of miles of roads. If we could take satellite-type images of the microscopic world, the impact of biotechnology would be no less obvious. The majority of the food we eat comes from engineered plants, which are modified either via modern technology or by more traditional artificial selection to grow without pesticides, to require fewer nutrients, or to withstand the rapidly changing climate. Manufacturers have substituted petroleum-based ingredients with biomaterials in many consumer goods, such as plastics, cosmetics, and fuels. Your laundry detergent? It almost certainly contains biotechnology. So do nearly all of your cotton clothes.

But perhaps the biggest application of biotechnology is in human health. Biotechnology is present in our lives before were even born, from fertility assistance to prenatal screening to the home pregnancy test. It follows us through childhood, with immunizations and antibiotics, both of which have drastically improved life expectancy. Biotechnology is behind blockbuster drugs for treating cancer and heart disease, and its being deployed in cutting-edge research to cure Alzheimers and reverse aging. The scientists behind the technology called CRISPR/Cas9 believe it may be the key to safely editing DNA for curing genetic disease. And one company is betting that organ transplant waiting lists can be eliminated by growing human organs in chimeric pigs.

Along with excitement, the rapid progress of research has also raised questions about the consequences of biotechnology advances. Biotechnology may carry more risk than other scientific fields: microbes are tiny and difficult to detect, but the dangers are potentially vast. Further, engineered cells could divide on their own and spread in the wild, with the possibility of far-reaching consequences. Biotechnology could most likely prove harmful either through the unintended consequences of benevolent research or from the purposeful manipulation of biology to cause harm. One could also imagine messy controversies, in which one group engages in an application for biotechnology that others consider dangerous or unethical.

Sugarcane farmers in Australia in the 1930s had a problem: cane beetles were destroying their crop. So, they reasoned that importing a natural predator, the cane toad, could be a natural form of pest control. What could go wrong? Well, the toads became a major nuisance themselves, spreading across the continent and eating the local fauna (except for, ironically, the cane beetle).

While modern biotechnology solutions to societys problems seem much more sophisticated than airdropping amphibians into Australia, this story should serve as a cautionary tale. To avoid blundering into disaster, the errors of the past should be acknowledged.

The world recently witnessed the devastating effects of disease outbreaks, in the form of Ebola and the Zika virus but those were natural in origin. The malicious use of biotechnology could mean that future outbreaks are started on purpose. Whether the perpetrator is a state actor or a terrorist group, the development and release of a bioweapon, such as a poison or infectious disease, would be hard to detect and even harder to stop. Unlike a bullet or a bomb, deadly cells could continue to spread long after being deployed. The US government takes this threat very seriously, and the threat of bioweapons to the environment should not be taken lightly either.

Developed nations, and even impoverished ones, have the resources and know-how to produce bioweapons. For example, North Korea is rumored to have assembled an arsenal containing anthrax, botulism, hemorrhagic fever, plague, smallpox, typhoid, and yellow fever, ready in case of attack. Its not unreasonable to assume that terrorists or other groups are trying to get their hands on bioweapons as well. Indeed, numerous instances of chemical or biological weapon use have been recorded, including the anthrax scare shortly after 9/11, which left 5 dead after the toxic cells were sent through the mail. And new gene editing technologies are increasing the odds that a hypothetical bioweapon targeted at a certain ethnicity, or even a single individual like a world leader, could one day become a reality.

While attacks using traditional weapons may require much less expertise, the dangers of bioweapons should not be ignored. It might seem impossible to make bioweapons without plenty of expensive materials and scientific knowledge, but recent advances in biotechnology may make it even easier for bioweapons to be produced outside of a specialized research lab. The cost to chemically manufacture strands of DNA is falling rapidly, meaning it may one day be affordable to print deadly proteins or cells at home. And the openness of science publishing, which has been crucial to our rapid research advances, also means that anyone can freely Google the chemical details of deadly neurotoxins. In fact, the most controversial aspect of the supercharged influenza case was not that the experiments had been carried out, but that the researchers wanted to openly share the details.

On a more hopeful note, scientific advances may allow researchers to find solutions to biotechnology threats as quickly as they arise. Recombinant DNA and biotechnology tools have enabled the rapid invention of new vaccines which could protect against new outbreaks, natural or man-made. For example, less than 5 months after the World Health Organization declared Zika virus a public health emergency, researchers got approval to enroll patients in trials for a DNA vaccine.

Biotechnology doesnt have to be deadly, or even dangerous, to fundamentally change our lives. While humans have been altering genes of plants and animals for millennia first through selective breeding and more recently with molecular tools and chimeras we are only just beginning to make changes to our own genomes (amid great controversy).

Cutting-edge tools like CRISPR/Cas9 and DNA synthesis raise important ethical questions that are increasingly urgent to answer. Some question whether altering human genes means playing God, and if so, whether we should do that at all. For instance, if gene therapy in humans is acceptable to cure disease, where do you draw the line? Among disease-associated gene mutations, some come with virtual certainty of premature death, while others put you at higher risk for something like Alzheimers, but dont guarantee youll get the disease. Many others lie somewhere in between. How do we determine a hard limit for which gene surgery to undertake, and under what circumstances, especially given that the surgery itself comes with the risk of causing genetic damage? Scholars and policymakers have wrestled with these questions for many years, and there is some guidance in documents such as the United Nations Universal Declaration on the Human Genome and Human Rights.

And what about ways that biotechnology may contribute to inequality in society? Early work in gene surgery will no doubt be expensive for example, Novartis plans to charge $475,000 for a one-time treatment of their recently approved cancer therapy, a drug which, in trials, has rescued patients facing certain death. Will todays income inequality, combined with biotechnology tools and talk of designer babies, lead to tomorrows permanent underclass of people who couldnt afford genetic enhancement?

Advances in biotechnology are escalating the debate, from questions about altering life to creating it from scratch. For example, a recently announced initiative called GP-Write has the goal of synthesizing an entire human genome from chemical building blocks within the next 10 years. The project organizers have many applications in mind, from bringing back wooly mammoths to growing human organs in pigs. But, as critics pointed out, the technology could make it possible to produce children with no biological parents, or to recreate the genome of another human, like making cellular replicas of Einstein. To create a human genome from scratch would be an enormous moral gesture, write two bioethicists regarding the GP-Write project. In response, the organizers of GP-Write insist that they welcome a vigorous ethical debate, and have no intention of turning synthetic cells into living humans. But this doesnt guarantee that rapidly advancing technology wont be applied in the future in ways we cant yet predict.

Its nearly impossible to imagine modern biotechnology without DNA sequencing. Since virtually all of biology centers around the instructions contained in DNA, biotechnologists who hope to modify the properties of cells, plants, and animals must speak the same molecular language. DNA is made up of four building blocks, or bases, and DNA sequencing is the process of determining the order of those bases in a strand of DNA. Since the publication of the complete human genome in 2003, the cost of DNA sequencing has dropped dramatically, making it a simple and widespread research tool.

Benefits: Sonia Vallabh had just graduated from law school when her mother died from a rare and fatal genetic disease. DNA sequencing showed that Sonia carried the fatal mutation as well. But far from resigning to her fate, Sonia and her husband Eric decided to fight back, and today they are graduate students at Harvard, racing to find a cure. DNA sequencing has also allowed Sonia to become pregnant, since doctors could test her eggs for ones that dont have the mutation. While most peoples genetic blueprints dont contain deadly mysteries, our health is increasingly supported by the medical breakthroughs that DNA sequencing has enabled. For example, researchers were able to track the 2014 Ebola epidemic in real time using DNA sequencing. And pharmaceutical companies are designing new anti-cancer drugs targeted to people with a specific DNA mutation. Entire new fields, such as personalized medicine, owe their existence to DNA sequencing technology.

Risks: Simply reading DNA is not harmful, but it is foundational for all of modern biotechnology. As the saying goes, knowledge is power, and the misuse of DNA information could have dire consequences. While DNA sequencing alone cannot make bioweapons, its hard to imagine waging biological warfare without being able to analyze the genes of infectious or deadly cells or viruses. And although ones own DNA information has traditionally been considered personal and private, containing information about your ancestors, family, and medical conditions, governments and corporations increasingly include a persons DNA signature in the information they collect. Some warn that such databases could be used to track people or discriminate on the basis of private medical records a dystopian vision of the future familiar to anyone whos seen the movie GATTACA. Even supplying patients with their own genetic information has come under scrutiny, if its done without proper context, as evidenced by the dispute between the FDA and the direct-to-consumer genetic testing service 23andMe. Finally, DNA testing opens the door to sticky ethical questions, such as whether to carry to term a pregnancy after the fetus is found to have a genetic mutation.

The modern field of biotechnology was born when scientists first manipulated or recombined DNA in a test tube, and today almost all aspects of society are impacted by so-called rDNA. Recombinant DNA tools allow researchers to choose a protein they think may be important for health or industry, and then remove that protein from its original context. Once removed, the protein can be studied in a species thats simple to manipulate, such as E. coli bacteria. This lets researchers reproduce it in vast quantities, engineer it for improved properties, and/or transplant it into a new species. Modern biomedical research, many best-selling drugs, most of the clothes you wear, and many of the foods you eat rely on rDNA biotechnology.

Benefits: Simply put, our world has been reshaped by rDNA. Modern medical advances are unimaginable without the ability to study cells and proteins with rDNA and the tools used to make it, such as PCR, which helps researchers copy and paste DNA in a test tube. An increasing number of vaccines and drugs are the direct products of rDNA. For example, nearly all insulin used in treating diabetes today is produced recombinantly. Additionally, cheese lovers may be interested to know that rDNA provides ingredients for a majority of hard cheeses produced in the West. Many important crops have been genetically modified to produce higher yields, withstand environmental stress, or grow without pesticides. Facing the unprecedented threats of climate change, many researchers believe rDNA and GMOs will be crucial in humanitys efforts to adapt to rapid environmental changes.

Risks: The inventors of rDNA themselves warned the public and their colleagues about the dangers of this technology. For example, they feared that rDNA derived from drug-resistant bacteria could escape from the lab, threatening the public with infectious superbugs. And recombinant viruses, useful for introducing genes into cells in a petri dish, might instead infect the human researchers. Some of the initial fears were allayed when scientists realized that genetic modification is much trickier than initially thought, and once the realistic threats were identified like recombinant viruses or the handling of deadly toxins safety and regulatory measures were put in place. Still, there are concerns that rogue scientists or bioterrorists could produce weapons with rDNA. For instance, it took researchers just 3 years to make poliovirus from scratch in 2006, and today the same could be accomplished in a matter of weeks. Recent flu epidemics have killed over 200,000, and the malicious release of an engineered virus could be much deadlier especially if preventative measures, such as vaccine stockpiles, are not in place.

Synthesizing DNA has the advantage of offering total researcher control over the final product. With many of the mysteries of DNA still unsolved, some scientists believe the only way to truly understand the genome is to make one from its basic building blocks. Building DNA from scratch has traditionally been too expensive and inefficient to be very practical, but in 2010, researchers did just that, completely synthesizing the genome of a bacteria and injecting it into a living cell. Since then, scientists have made bigger and bigger genomes, and recently, the GP-Write project launched with the intention of tackling perhaps the ultimate goal: chemically fabricating an entire human genome. Meeting this goal and within a 10 year timeline will require new technology and an explosion in manufacturing capacity. But the projects success could signal the impact of synthetic DNA on the future of biotechnology.

Benefits: Plummeting costs and technical advances have made the goal of total genome synthesis seem much more immediate. Scientists hope these advances, and the insights they enable, will ultimately make it easier to make custom cells to serve as medicines or even bomb-sniffing plants. Fantastical applications of DNA synthesis include human cells that are immune to all viruses or DNA-based data storage. Prof. George Church of Harvard has proposed using DNA synthesis technology to de-extinct the passenger pigeon, wooly mammoth, or even Neanderthals. One company hopes to edit pig cells using DNA synthesis technology so that their organs can be transplanted into humans. And DNA is an efficient option for storing data, as researchers recently demonstrated when they stored a movie file in the genome of a cell.

Risks: DNA synthesis has sparked significant controversy and ethical concerns. For example, when the GP-Write project was announced, some criticized the organizers for the troubling possibilities that synthesizing genomes could evoke, likening it to playing God. Would it be ethical, for instance, to synthesize Einsteins genome and transplant it into cells? The technology to do so does not yet exist, and GP-Write leaders have backed away from making human genomes in living cells, but some are still demanding that the ethical debate happen well in advance of the technologys arrival. Additionally, cheap DNA synthesis could one day democratize the ability to make bioweapons or other nuisances, as one virologist demonstrated when he made the horsepox virus (related to the virus that causes smallpox) with DNA he ordered over the Internet. (It should be noted, however, that the other ingredients needed to make the horsepox virus are specialized equipment and deep technical expertise.)

Many diseases have a basis in our DNA, and until recently, doctors had very few tools to address the root causes. That appears to have changed with the recent discovery of a DNA editing system called CRISPR/Cas9. (A note on terminology CRISPR is a bacterial immune system, while Cas9 is one protein component of that system, but both terms are often used to refer to the protein.) It operates in cells like a DNA scissor, opening slots in the genome where scientists can insert their own sequence. While the capability of cutting DNA wasnt unprecedented, Cas9 dusts the competition with its effectiveness and ease of use. Even though its a biotech newcomer, much of the scientific community has already caught CRISPR-fever, and biotech companies are racing to turn genome editing tools into the next blockbuster pharmaceutical.

Benefits: Genome editing may be the key to solving currently intractable genetic diseases such as cystic fibrosis, which is caused by a single genetic defect. If Cas9 can somehow be inserted into a patients cells, it could fix the mutations that cause such diseases, offering a permanent cure. Even diseases caused by many mutations, like cancer, or caused by a virus, like HIV/AIDS, could be treated using genome editing. Just recently, an FDA panel recommended a gene therapy for cancer, which showed dramatic responses for patients who had exhausted every other treatment. Genome editing tools are also used to make lab models of diseases, cells that store memories, and tools that can detect epidemic viruses like Zika or Ebola. And as described above, if a gene drive, which uses Cas9, is deployed effectively, we could eliminate diseases such as malaria, which kills nearly half a million people each year.

Risks: Cas9 has generated nearly as much controversy as it has excitement, because genome editing carries both safety issues and ethical risks. Cutting and repairing a cells DNA is not risk-free, and errors in the process could make a disease worse, not better. Genome editing in reproductive cells, such as sperm or eggs, could result in heritable genetic changes, meaning dangerous mutations could be passed down to future generations. And some warn of unethical uses of genome editing, fearing a rise of designer babies if parents are allowed to choose their childrens traits, even though there are currently no straightforward links between ones genes and their intelligence, appearance, etc. Similarly, a gene drive, despite possibly minimizing the spread of certain diseases, has the potential to create great harm since it is intended to kill or modify an entire species. A successful gene drive could have unintended ecological impacts, be used with malicious intent, or mutate in unexpected ways. Finally, while the capability doesnt currently exist, its not out of the realm of possibility that a rogue agent could develop genetically selective bioweapons to target individuals or populations with certain genetic traits.

Videos

Research Papers

Books

Informational Documents

Articles

Organizations

The organizations above all work on biotechnology issues, though many cover other topics as well. This list is undoubtedly incomplete; please contact us to suggest additions or corrections.

Special thanks to Jeff Bessen for his help researching and writing this page.

See the rest here:
Benefits & Risks of Biotechnology - Future of Life Institute

Dublin, March 24, 2020 (GLOBE NEWSWIRE) -- The "Agricultural Biotechnology: Emerging Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The study scope includes key agricultural biotechnology tools (i.e., next-generation DNA sequencing, biochips, RNA interference, synthetic biology tools, and gene editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

The report analyzes these technologies and products to determine present and future market sizes, and to forecast growth from 2019 through 2024. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status and market driving forces.

The research provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS and microarray companies); major seed companies; biotech trait companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2018 and 2019.

96 agricultural and biotechnology companies are profiled in this report.

The report includes:

32 data tables and 60 additional tables

A detailed review of the global markets for agricultural biotechnology and other emerging technologies

Analyses of the global market trends with data from 2018 to 2019, and projections of compound annual growth rates (CAGRs) through 2024

Discussion of key agricultural biotechnology tools such as next-generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools, and assaying their role in enhancing the marketplace

Underlying market opportunities for biotechnology tools, genomic-enabled products, and biotech seeds enhancing growth for the coming five years

Key merger and acquisitions, joint ventures, and alliances within the large biotechnology companies, allowing them to participate in the upside of new genomics technologies that will enhance their breeding, seed development, and biologics programs

Company profiles of market-leading participants, Ajinomoto Co, BASF, Cibus, Novozymes, Oxford Nanopore Technologies, and Qiagen

Market Insights

Story continues

Global megatrends are driving the need for higher agricultural yields, creating strong tailwinds for innovative seed traits and biological pesticides and stimulants.

World population growth, coupled with rising incomes, lead to consumption of higher-quality foods, including meat. This, in turn, creates higher consumption of feed crops, including maize, soy, and wheat. At the same time, the total acreage of arable land available for producing crops is under pressure from a range of forces, including growing populations, urbanization, and global warming.

These global forces are creating leverage in the industry to increase productivity and crop yields. Biotechnology provides strategic tools for the agricultural industry to meet these market demands. This report examines the role of these technologies in agriculture and quantifies their market impact.

Reasons for Doing the Study

Agriculture is a fundamental and strategic component of a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields and other desirable traits. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader. The report does this by examining the main product applications and markets, thereby helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments, in order to help the reader better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, gene editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Scope of Report

Agricultural Biotechnology Market

Industry Growth Driving Forces

Life Cycle Status

Agricultural Biotechnology Industry

Chapter 4 Technology Background

Introduction to Crop Technologies

Plant Modification Platforms

Agricultural Biotechnology Tools

Next-Generation Sequencing

Biochips

RNA Interference

Gene Editing

Synthetic Biology

Seed Technologies

Development of a Genetically Modified Seed

Agricultural Biologicals

Chapter 5 Agricultural Biotechnology Applications

Applications Overview

DNA Sequencing Applications

Biochip Applications

RNAi Applications

RNAi-based Insecticides

RNAi-based Crop Traits

Advantages of RNAi in Agriculture

Synthetic Biology Applications

Biofuels

Renewable Chemicals

Gene Editing and Engineering Applications

Chapter 6 DNA Read, Write and Edit Industries

Agricultural Seed Genomics Industry

Biotech Traits Industry

Sequencing Industry

Sequencing Instruments Industry

Long Read Sequencing Industry

Gene Editing Industry

Agricultural Biologicals Industry

Chapter 7 Acquisitions and Strategic Alliances

Chapter 8 Agricultural Biotechnology Markets

Forces Driving Industry Growth

Global Demographic and Land Use Trends

Demand for Higher Yields

Rise of the Middle Class in Developing Countries

Advances in DNA Read, Write and Edit Technologies

New Commercialization Pathways

Emergence of Critical Mass in Plant Traits Industry

Market Summary

Market for Agricultural Biotechnology Tools

Biochips

Gene Editing Tools

RNAi Tools

DNA Sequencing

Synthetic Biology Tools

RNAi Market

Gene Editing Market

Gene-edited Biologicals

Gene-edited Seeds

Biotech Seed Market

Synthetic Biology Market

Polymers

Enzymes

Other Renewables

Biofuels

Biologicals Market

Agricultural Biotechnology Regional Markets

Agricultural Biotechnology Market by Region

Market for Biotechnology Tools, by Region

Synthetic Biology-Enabled Market by Region

Biologicals Market by Region

Market for Biotechnology Seeds by Region

Chapter 9 Patents

Sequencing-Related Patent Issues

Synthetic Biology Industry Patent Analysis

View post:
Global Agricultural Biotechnology Markets, 2018-2024 - Discussion of the Opportunities in Biotechnology Tools, Genomic-Enabled Products and Biotech...

Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people.

The company said that human tests of the drugs could begin in three to five months, putting it roughly in line with two other efforts to produce anti-coronavirus antibodies. Regeneron, based in Tarrytown, N.Y., has said that its antibodies could enter trials by early summer and that its treatment, if it proves effective, could be available for some uses in the fall. Eli Lilly, which is developing anti-SARS-CoV-2 antibodies with AbCellera, a Vancouver biotech, has said it hopes to begin human tests in four months.

Stopping this disease will take a combination of prevention and treatment approaches, Vir CEO George Scangos said in a statement. At Vir, we are fortunate that our existing antibody platform gave us a running start against COVID-19, and we have the internal and partnered capabilities to work on multiple approaches.

advertisement

Vir is working with the Cambridge, Mass., biotech firm Biogen, where Scangos was previously CEO, and Wuxi Biologics, a China-based manufacturing organization.

Antibodies are a part of the immune system that drug companies have learned to weaponize as treatments for diseases. An antibody drug against SARS-CoV-2 might either treat infection in very sick patients or prevent infection. It is one of many techniques researchers are attempting against Covid-19. For a rundown of approaches, see this story.

advertisement

Vir is taking a somewhat different approach from Regeneron. While Regeneron is going to choose two antibodies to use together, Vir has picked a single antibody. But Vir is modifying it in two different ways and testing the resulting two experimental drugs in parallel.

The first modification should make the antibodies last longer in the body, and is being done to both candidates. The second, in animal models, leads to long-term production of white blood cells that might lead to long-term immunity, as with a vaccine. If this proves effective, the antibody could be used to prevent infection.

Vir said it has also identified other antibodies that work differently, so that they might be combined with the two it is testing. And it is continuing to search for antibodies in the blood or patients who have survived SARS-CoV-2.

Visit link:
Vir Biotechnology reports early progress in antibody treatment for Covid-19 - STAT

Ottawa, Canada, March 19, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage biotechnology company, today announced that it will be presenting an update on the companys development program at the BIO-Europe Spring 2020 meeting, originally planned to be held in Paris, France. Due to the SARS-CoV-2 pandemic, the presentation will be part of a virtual event.

The presentation will be given by Dr. Ian McGowan who is the Chief Medical Officer at Orion Biotechnology. Highlights of the presentation will include an update on the Orion proprietary discovery platform, progress towards filing an IND to support a US/European Phase 1/2 oncology program, and the progress of their Phase 1 safety and acceptability study of the topical formulation of OB-002 that is currently ongoing in Poland. There will also be a brief discussion around a potential role for OB-002 in treating COVID-19-associated acute respiratory distress syndrome (ARDS).

Mark Groper, President and CEO of Orion Biotechnology said 2020 is shaping up to be a very busy year for Orion Biotechnology. I am delighted that our Phase 1 study in Poland is almost completed and that we are moving closer towards filing regulatory submissions for OB-002 as an innovative immunotherapy candidate for patients with advanced cancer. Our discovery platform is already showing its capability by generating multiple novel hits that may have the potential to be of significant therapeutic value in a broad range of medical indications.

Ian McGowan MD PhD, Chief Medical Officer at Orion Biotechnology said We are delighted at the progress that we have made on multiple fronts over the last 12 months. Our Phase 1 study in Poland of the topical formulation of OB-002 has just enrolled the last participant and we look forward to presenting data later this year. Progression towards regulatory filings in support of our oncology program in Q4 2020 is proceding well and our discovery platform is generating new hits. We are also actively exploring whether OB-002 may have a role in the management of SARS-CoV-2 infection.

A link to the recording of Dr. McGowans presentation will be available from the Bio-Europe Spring website at; https://informaconnect.com/bioeurope-spring/presenting-companies-bio-europe-spring/

About Orion Biotechnology Canada, Ltd.

Orion Biotechnology Canada Ltd, is a clinical stage privately held pharmaceutical company focused on immune-oncology as wel as the discovery and developmebt of chemokine analogs a promising new class of drugs with broad therapeutic applications. Orion is using its novel and proprietary drug discovery platform to facilitate rapid and low cost developmet of its molecules. Orions lead candidate, OB-002, is a first-in-class chemokine analogue and best in class CCR5 antagonist. Our close ties to diverse institutions and experts around the globe, as well as our proprietary drug discovery platform, continue to stimulate the rapid discovery of promising new treatments. Learn more at http://www.orionbiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking information, which reflects Orions current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orions control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Ross MacLeodOrion Biotechnology Canada Ltd.+1 343.291.1032ross@orionbiotechnology.com

Read this article:
Orion Biotechnology to Present at the BIO-Europe Spring 2020 Virtual Event - Yahoo Finance

Board additions will enhance Companys ability to execute on key corporate initiatives

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc.. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments are designed to strengthen the Company as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. The new Board members include Brent Longnecker, Chief Executive Officer of Longnecker & Associates, Jose A. Moreno Toscano, Chief Executive Officer of LFB USA Inc, and William R. (Will) Wilson, Jr., Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co.

This strengthening of the Board of Directors closely follows the Company receiving Fast Track Designation from the Food and Drug Administration (FDA) for its lead drug candidate, raising more than $26 million from institutional investors over the last few months, and licensing a new gene therapy drug candidate for diabetes from the University of Pittsburgh. Also, just yesterday, the Company announced that it strengthened its management team by adding two new senior executives, Catherine Vaczy as Executive Vice President and Chief Strategy Officer, and Michael Redman as Executive Vice President and Chief Operating Officer.

We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company, said Rodney Varner, Chief Executive Officer of Genprex. Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to our develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.

Brent Longnecker has more than 30 years of experience in corporate governance, executive compensation, and risk management consulting for public, private, and non-profit organizations. Mr. Longnecker built one of the countrys leading privately-held executive compensation and corporate governance consultancies, serving both domestic and international markets. Mr. Longnecker has deep expertise in healthcare, energy, real estate, manufacturing, and financial companies, regularly consulting with boards of directors, CEOs, key executives, and advisors in many major industries. He is a prolific author on the subjects of executive compensation and corporate governance.

Jose A. Moreno Toscano brings to the Company over 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations, and general management.

William R. Wilson, Jr. has more than 40 years of experience as an attorney, with legal experience spanning health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, and contractual matters. He previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, as well as Assistant District Attorney for Dallas County, Texas.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso). For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding our possible commercial partnerships and regarding our financial resources. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; our ability to enter into strategic partnerships and the success of those partnerships; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates; and the extent and duration of the current and future economic challenges we may face. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005120/en/

Originally posted here:
Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders - BioSpace

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) that it has lifted the hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX.

Since pluripotent stem cells are capable of differentiating into all human cell types potentially genetically modified in any manner, they open the door to a wide array of new therapies, stated Dr. Michael D. West, PhD, founder and CEO of AgeX. This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications.

IMS001 is a formulation of cells derived from AgeX pluripotent stem cells induced to differentiate into mesenchymal cells (hES-MSC) and through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases. IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. ImStem believes this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA. ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.

The clinical-grade pluripotent stem cell lines from AgeX were the first published GMP-compatible lines ever created, said Xiaofang Wang, MD, PhD, Founder and Chief Technology Officer of ImStem. As such, they have been widely distributed in the scientific community and demonstrated to meet the needs of industry for relatively rapid product development.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About IMS001

IMS001 is an investigational, allogeneic, hES-MSC that has undergone IND-enabling, preclinical biodistribution, engraftment, tumorigenicity, toxicology, immunogenicity, and pharmacology studies. IMS001 has demonstrated preclinical immunomodulatory activities, which may lead to potential therapeutic benefits in a wide array of neurological, autoimmune, and rare orphan diseases with high unmet medical needs.

Previously published in-vitro data, in collaboration with scientists at the University of Connecticut (UConn) Health, have demonstrated potential advantages of hESC-MSCs in terms of their immunomodulatory effects, as well as the potential to stabilize the blood-brain-barrier (BBB). These mechanistic properties may lead to therapeutic benefits in diseases such as MS, potentially reducing relapses, disability progression, and inducing disease arrest.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The companys mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology, Inc. is a privately held company headquartered in Farmington, CT. For more information, visit http://www.imstem.com.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Originally posted here:
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for...

The Global Food Biotechnology Market is expected to grow from USD 17,523.65 Million in 2018 to USD 32,563.78 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.25%.The latest report on Food Biotechnology Market added by Regal Intelligence, focus on market estimates and geographical spectrum of this industry. The report specifies information about Food Biotechnology industry regarding a thorough and detailed assessment of this business.

Further, the Food Biotechnology Market report details important challenges and factors that influence market growth. Further, a detailed comprehensive secondary research was done to collect information on the market segments and sub-segments. Further, primary research was performed to validate the assumptions and findings obtained from secondary research with industry professionals and experts.

Request Free Sample Report at https://www.regalintelligence.com/request-sample/24665

Competitive Landscape:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Food Biotechnology Market including are AquaBounty Technologies, BASF SE, Bayer CropScience AG, CropScience AG, Dow AgroSciences LLC, ABS Global, Arcadia Biosciences, BDF Ingredients Zuchem, Camson Bio Technologies Ltd, and Monsanto. On the basis of Type, the Global Food Biotechnology Market is studied across Synthetic Biology Derived Products and Transgenic.On the basis of Application, the Global Food Biotechnology Market is studied across Animals, Microorganisms, and Plants.

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this Food Biotechnology Market report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers, and producers etc.

The primary sources from the demand side include Food Biotechnology industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, End-User (product buyers), and related key executives from various key companies and organizations operating in the global Food Biotechnology market.

Primary Types of the industry are

Primary Applications of the industry are

Ask For Table of [emailprotected] https://www.regalintelligence.com/request-toc/24665

This report is based on the synthesis, analysis, and interpretation of information collected on the Food Biotechnology market from various sources. Our analysts have analysed the information & data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the Food Biotechnology Industry.

The following market parameters were considered to estimate market value:

Market Overview

The report includes overviews market introduction, market drivers & influencing factors, restraints & challenges, and potential growth opportunities of Food Biotechnology market. The report consists of market evaluation tools such as Porters five forces, PESTLE Analysis, and value chain analysis.

Key Questions Addressed in the Report:

For more information and discount on this report, reach us at: https://www.regalintelligence.com/check-discount/24665

Thank you for Reading this article.

Link:
Learn global specifications of the Food Biotechnology Market - Monroe Scoop

The Food BiotechnologyMarketanalysis summary by Reports monitor is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

TheTop Leading players operating in the market: Covered in this Report: ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies Ltd, Dow AgroSciences LLC, DuPont Pioneer, Evogene Ltd, Hy-Line International, KWS Group, Monsanto, Origin Agritech Limited, Syngenta AG & More.

To Download PDF Sample Report, With 30 mins free consultation! Click Here: https://www.reportsmonitor.com/request_sample/886167

The research report provides a detailed analysis of the current and historical market trends, development patterns, and the correlations between the market dynamics and forecasts, as well as the hard-hitting market facts. The global Food Biotechnology market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights. The report also takes into account the market drivers, restraints, challenges, threats, and the potential growth opportunities, influencing the growth pattern of the key market segments. The section also focuses on the key micro- and macroeconomic factors impacting the growth of the overall Food Biotechnology market.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):Transgenic CropsSynthetic Biology Derived ProductsApplication Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):AnimalsPlantsOthers

Global Food BiotechnologyMarket: Regional Segmentation

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! Please click [emailprotected]https://www.reportsmonitor.com/check_discount/886167

The analysis objectives of this report are:

Key Questions Answered:

Click to view the full report details, Reports TOC, Figure and [emailprotected]https://www.reportsmonitor.com/report/886167/Food-Biotechnology-Market

Research MethodologyReports Monitor uses trustworthy primary and secondary research sources to compile its reports. It also relies on latest research techniques to prepare highly detailed and accurate research studies such as this one here. It uses data triangulation, top down and bottom up approaches, and advanced research processes to come out with comprehensive and industry-best market research reports

Contact UsJay MatthewsDirect: +1 513 549 5911 (U.S.)+44 203 318 2846 (U.K.)Email: [emailprotected]

The rest is here:
Innovative Report on Food Biotechnology Market with Competitive Analysis, New Business Developments and Top Companies ABS Global, Arcadia Biosciences,...

Dublin, March 24, 2020 (GLOBE NEWSWIRE) -- The "Microsphere Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025.

According to this market report, the future of the global microsphere market looks promising with opportunities in the composites, medical technology, life science & biotechnology, and painting & coating industries. The major drivers for this market are the growing demand for higher efficiency and lightweight materials and superior structural and enhanced properties of microsphere over conventional fillers.

Emerging trends, which have a direct impact on the dynamics of the industry, include continuous research and development to improve the drug delivery system and the development of biodegradable microspheres.

The study includes trends and forecast for the global microsphere market by product type, end-use industry, material, and the region.

Some of the microsphere companies profiled in this report include 3M, Cospheric, Trelleborg, and AkzoNobel Expancel.

It is forecast that the glass microsphere will remain the largest material segment over the forecast period, as it provides lower viscosity, a high melting point, and higher chemical resistance than other types of microsphere.

Composites is projected to remain the largest end-use industry, and it is also expected to witness the highest growth during the forecast period due to the increasing demand for lightweight materials in various end-use industries.

North America will remain the largest region, and it is also expected to witness the highest growth over the forecast period due to the increasing demand for composites in automobiles and growth in medical technology.

Some of the features of the report include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global microsphere market by end-use industry (Composites, Medical Technology, Life Sciences & Biotechnology, Paints & Coatings, Cosmetics & Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2 Which segments will grow at a faster pace and why?Q.3 Which regions will grow at a faster pace and why?Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?Q.5 What are the business risks and threats to the market?Q.6 What are emerging trends in this market and the reasons behind them? Q.7 What are some changing demands of customers in the market?Q.8 What are the new developments in the market? Which companies are leading these developments? Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?

Key Topics Covered

1. Executive Summary

2. Market Background and Classifications2.1: Introduction, Background, and Classification2.2: Supply Chain2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2014 to 20253.1: Macroeconomic Trends (2014-2019) and Forecast (2020-2025)3.2: Global Microsphere Market Trends (2014-2019) and Forecast (2020-2025)3.3: Global Microsphere Market by Product Type3.3.1: Hollow Microspheres3.3.2: Solid Microsphere3.4: Global Microsphere Market by End-use Industry3.4.1: Composites 3.4.2: Medical Technology 3.4.3: Life Sciences and Biotechnology 3.4.4: Cosmetics and Personal Care 3.4.5: Paint and Coatings3.4.6: Others3.5: Global Microsphere Market by Material3.5.1: Glass Microsphere3.5.2: Polymer Microsphere3.5.3: Ceramic Microsphere3.5.4: Fly Ash Microsphere3.5.5: Metallic Microsphere3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2014 to 20254.1: Global Microsphere Market by Region4.2: North American Microsphere Market4.2.1: Market by End-use Industry4.2.2: Market by Product Type4.2.3: Market by Material4.2.4: The US Microsphere Market4.2.5: Canadian Microsphere Market4.2.6: Mexican Microsphere Market4.3: European Microsphere Market4.4: APAC Microsphere Market4.5: RoW Microsphere Market

5. Competitor Analysis5.1: Product Portfolio Analysis5.2: Market Share Analysis5.3: Geographical Reach5.4: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis6.1: Growth Opportunity Analysis6.1.1: Growth Opportunities for the Global Microsphere Market by End-use Industry6.1.2: Growth Opportunities for the Global Microsphere Market by Product Type6.1.3: Growth Opportunities for the Global Microsphere Market by Material6.1.4: Growth Opportunities for the Global Microsphere Market by Region6.2: Emerging Trends in the Global Microsphere market6.3: Strategic Analysis6.3.1: New Product Development6.3.2: Capacity Expansion in the Global Microsphere market6.3.3: Certification and Licensing6.3.4: Merger and Acquisition

7. Company Profiles of Leading Players7.1: 3M7.2: Potters Industries LLC7.3: AkzoNobel N.V.7.4: Trelleborg AB7.5: Chase Corporation7.6: Matsumoto Yushi-Seiyaku Co. Ltd.7.7: Momentive Performance Materials Inc.7.8: Luminex Corporation7.9: Thermo Fisher Scientific7.10: Sigmund Lindner GmbH

For more information about this report visit https://www.researchandmarkets.com/r/c9ai0o

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View post:
Microsphere Industry Outlook, 2025: Promising Opportunities in the Composites, Medical Technology, Life Science & Biotechnology, and Painting...

DUBLIN--(BUSINESS WIRE)--The "Epigenetic Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The future of the epigenetic market looks promising with opportunities in the pharmaceutical and biotechnology industries. The global epigenetic market is expected to grow with a CAGR of 14% from 2019 to 2024. The major growth drivers for this market are declining sequencing costs and time, increasing research activities and availability of government funding, and rising cancer prevalence.

A report of more than 150 pages is developed to help in your business decisions. To learn the scope of, benefits, companies researched and other details of the epigenetic market, then read this report.

Some of the features of Global Epigenetic Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global epigenetic market by product, application, technology, and region?

Q.2 Which segments will grow at a faster pace and why?

Q.3 Which regions will grow at a faster pace and why?

Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the epigenetic market?

Q.5 What are the business risks and threats to the epigenetic market?

Q.6 What are emerging trends in this epigenetic market and the reasons behind them?

Q.7 What are some changing demands of customers in the epigenetic market?

Q.8 What are the new developments in the epigenetic market? Which companies are leading these developments?

Q.9 Who are the major players in this epigenetic market? What strategic initiatives are being implemented by key players for business growth?

Q.10 What are some of the competitive products and processes in this epigenetic area and how big of a threat do they pose for loss of market share via material or product substitution?

Q.11 What M & A activities have taken place in the last 5 years in epigenetic market?

Key Topics Covered:

1. Executive Summary

2. Market Background and Classifications

2.1: Introduction, Background, and Classifications

2.2: Supply Chain

2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

3.1: Macroeconomic Trends and Forecast

3.2: Global Epigenetic Market: Trends and Forecast

3.3: Global Epigenetic Market by Product Type

3.3.1: Enzymes

3.3.2: Kits

3.3.3: Reagents

3.3.4: Bioinformatics Tools

3.4: Global Epigenetic Market by Application

3.4.1: Oncology

3.4.2: Non Oncology

3.5: Global Epigenetic Market by End Use Industry

3.5.1: Pharmaceutical

3.5.2: Biotechnology

3.5.3: Others

3.6: Global Epigenetic Market by Technology

3.6.1: DNA Methylation

3.6.2: Histone Methylation

3.6.3: Histone Acetylation

3.6.4: Large Noncoding RNA

3.6.5: MicroRNA Modification

3.6.6: Chromatin structures

3.6.7: Others

4. Market Trends and Forecast Analysis by Region

4.1: Global Epigenetic Market by Region

4.2: North American Epigenetic Market

4.2.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.2.2: Market by Application: Oncology and Non Oncology

4.2.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.2.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.3: European Epigenetic Market

4.3.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.3.2: Market by Application: Oncology and Non Oncology

4.3.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.3.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.4: APAC Epigenetic Market

4.4.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.4.2: Market by Application: Oncology and Non Oncology

4.4.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.4.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.5: Row Epigenetic Market

4.5.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.5.2: Market by Application: Oncology and Non Oncology

4.5.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.5.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis

5.2: Market Share Analysis

5.3: Operational Integration

5.4: Geographical Reach

5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis

6.1.1: Growth Opportunities for Global Epigenetic Market by Product Type

6.1.2: Growth Opportunities for Global Epigenetic Market by Application

6.1.3: Growth Opportunities for Global Market by End Use Industry

6.1.4: Growth Opportunities for Global Market by Technology

6.1.5: Growth Opportunities for Global Epigenetic Market by Region

6.2: Emerging Trends in Global Epigenetic Market

6.3: Strategic Analysis

6.3.1: New Product Development

6.3.2: Capacity Expansion of Global Epigenetic Market

6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players

7.1: Illumina

7.2: Thermo Fisher Scientific

7.3: Merck Millipore

7.4: Abcam

7.5: Active Motif

7.6: Bio-Rad

Read more:
Global Epigenetic Market Expected to Grow with a CAGR of 14%, 2019-2024 - ResearchAndMarkets.com - Business Wire